| 30/07/2025 | UBS Group AG | 1314(L) | 66,000(L) | | 176,879,357(L) | 6.03 | | 22/07/2025 | UBS Group AG | 1314(L) | 862,000(L) | | 177,102,634(L) | 6.04 | | 15/07/2025 | UBS Group AG | 1314(L) | 1,676,000(L) | | 177,222,088(L) | 6.04 | | 14/07/2025 | UBS Group AG | 1305(L) | 520,000(L) | | 182,068,088(L) | 6.20 | | 11/06/2025 | UBS Group AG | 1201(L) | -3,192,000(L) | HKD 2.979(L) | 204,947,540(L) | 6.98 | | 03/06/2025 | UBS Group AG | 1201(L) | -7,726,000(L) | HKD 2.970(L) | 228,790,696(L) | 7.77 | | 19/05/2025 | 曲繼廣 | 1113(L) | +500,000(L) | HKD 2.930(L) | 1,168,982,000(L) | 39.61 | | 19/05/2025 | China Pharmaceutical Company Limited | 1710(L) | +500,000(L) | HKD 2.930(L) | 877,764,000(L) | 29.74 | | 16/05/2025 | 曲繼廣 | 1113(L) | +1,776,000(L) | HKD 2.886(L) | 1,168,482,000(L) | 39.59 | | 16/05/2025 | China Pharmaceutical Company Limited | 1710(L) | +1,776,000(L) | HKD 2.886(L) | 877,264,000(L) | 29.72 | | 29/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD 2.955(L) | 875,488,000(L) | 29.64 | | 29/04/2025 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD 2.955(L) | 1,166,706,000(L) | 39.50 | | 16/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +1,400,000(L) | HKD 2.954(L) | 874,488,000(L) | 29.60 | | 16/04/2025 | 曲繼廣 | 1113(L) | +1,400,000(L) | HKD 2.954(L) | 1,165,706,000(L) | 39.46 | | 15/04/2025 | 曲繼廣 | 1101(L) | +580,000(L) | HKD 3.032(L) | 1,164,306,000(L) | 39.41 | | 11/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +800,000(L) | HKD 3.011(L) | 873,088,000(L) | 29.55 | | 11/04/2025 | 曲繼廣 | 1113(L) | +800,000(L) | HKD 3.011(L) | 1,163,726,000(L) | 39.39 | | 09/04/2025 | 曲繼廣 | 1113(L) | +300,000(L) | HKD 3.021(L) | 1,162,926,000(L) | 39.37 | | 09/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +300,000(L) | HKD 3.021(L) | 872,288,000(L) | 29.53 | | 07/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +6,000,000(L) | HKD 3.006(L) | 871,988,000(L) | 29.52 | | 07/04/2025 | 曲繼廣 | 1113(L) | +6,000,000(L) | HKD 3.006(L) | 1,162,626,000(L) | 39.36 | | 03/04/2025 | 曲繼廣 | 1113(L) | +3,000,000(L) | HKD 3.355(L) | 1,156,626,000(L) | 39.15 | | 03/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +3,000,000(L) | HKD 3.355(L) | 865,988,000(L) | 29.31 | | 01/04/2025 | 曲繼廣 | 1113(L) | +3,000,000(L) | HKD 3.363(L) | 1,152,226,000(L) | 39.01 | | 01/04/2025 | 曲繼廣 | 1101(L) | +1,400,000(L) | HKD 3.374(L) | 1,153,626,000(L) | 39.05 | | 01/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +3,000,000(L) | HKD 3.363(L) | 862,988,000(L) | 29.22 | | 31/03/2025 | China Pharmaceutical Company Limited | 1710(L) | +2,800,000(L) | HKD 3.191(L) | 859,988,000(L) | 29.11 | | 31/03/2025 | 曲繼廣 | 1113(L) | +2,800,000(L) | HKD 3.191(L) | 1,149,226,000(L) | 38.90 | | 21/02/2025 | UBS Group AG | 1201(L) | -372,000(L) | HKD 3.244(L) | 265,496,063(L) | 8.98 | | 20/02/2025 | UBS Group AG | 1101(L) | +198,000(L) | HKD 3.335(L) | 265,867,466(L) | 9.00 | | 18/02/2025 | UBS Group AG | 1201(L) | -448,204(L) | HKD 3.238(L) | 265,697,464(L) | 8.99 | | 08/01/2025 | 曲繼廣 | 1113(L) | +500,000(L) | HKD 3.263(L) | 1,146,426,000(L) | 38.76 | | 08/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +500,000(L) | HKD 3.263(L) | 857,188,000(L) | 28.98 | | 07/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +600,000(L) | HKD 3.337(L) | 856,688,000(L) | 28.96 | | 07/01/2025 | 曲繼廣 | 1113(L) | +600,000(L) | HKD 3.337(L) | 1,145,926,000(L) | 38.74 | | 06/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +600,000(L) | HKD 3.388(L) | 856,088,000(L) | 28.94 | | 06/01/2025 | 曲繼廣 | 1113(L) | +600,000(L) | HKD 3.388(L) | 1,145,326,000(L) | 38.72 | | 03/01/2025 | 曲繼廣 | 1113(L) | +660,000(L) | HKD 3.372(L) | 1,144,726,000(L) | 38.70 | | 03/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +660,000(L) | HKD 3.372(L) | 855,488,000(L) | 28.92 | | 26/11/2024 | 曲繼廣 | 1101(L) | +1,300,000(L) | HKD 3.490(L) | 1,144,066,000(L) | 38.68 | | | 1 2 3 4 5 |
|